{"id":3192,"company":{"country":"US","currency":"USD","exchange":"NEW YORK STOCK EXCHANGE, INC.","ipo":"2013-02-01","marketCap":69710.4,"name":"Zoetis Inc","phone":"19738227000.0","outstanding":460.32,"symbol":"ZTS","website":"https://www.zoetis.com/","industry":"Pharmaceuticals"},"price":167.075,"year":2024,"month":3,"day":27,"weekday":"Wednesday","title":"Historical Revenue Growth Trends of Zoetis Inc","date":"2024-03-27","url":"/posts/2024/03/27/ZTS","content":[{"section":"Revenue Growth Overview","text":"Zoetis Inc has consistently shown strong revenue growth over the years, indicating a healthy and thriving business. The company's revenue has steadily increased, with some fluctuations due to external factors such as market conditions and economic downturns."},{"section":"Historical Revenue Growth Data","text":"Here is some historical revenue growth data for Zoetis Inc:\n\n- 2016: $4.9 billion\n- 2017: $5.31 billion (8.37% growth)\n- 2018: $5.83 billion (9.81% growth)\n- 2019: $6.26 billion (7.36% growth)\n- 2020: $6.71 billion (7.18% growth)"},{"section":"Implications for Investors","text":"The consistent revenue growth of Zoetis Inc indicates a strong market presence and successful product offerings. This trend suggests that the company has been able to effectively capitalize on the growing demand for animal health products. Investors may take this as a positive sign and consider Zoetis Inc as a potential investment opportunity in the animal health industry."},{"section":"Factors Affecting Revenue Growth","text":"Several factors contribute to Zoetis Inc's revenue growth, including:\n\n1. Innovation: The company's ongoing investment in research and development allows for the introduction of new and improved products, driving revenue growth.\n2. Global Expansion: Zoetis Inc has expanded its operations to various regions globally, tapping into new markets and driving revenue growth.\n3. Increased Awareness: Growing awareness about the importance of animal health and the need for quality veterinary products has led to an increased demand for Zoetis Inc's offerings."},{"section":"Conclusion","text":"Zoetis Inc has demonstrated consistent revenue growth over the years, indicating a successful and thriving business. Investors may consider this trend as a positive signal for potential investment in Zoetis Inc, given its strong market presence, innovative product offerings, and expansion efforts."}],"tags":["OverSold","Long","Pharmaceuticals"],"news":[{"category":"company","date":1711463234,"headline":"UPDATE 2-Zoetis in EU antitrust crosshairs over rival dog pain medicine","id":126691732,"image":"","symbol":"ZTS","publisher":"Yahoo","summary":"EU antitrust regulators have started an investigation into whether Zoetis blocked the market launch of a rival pain medicine for dogs, the European Commission said on Tuesday, a move that could result in a hefty fine for the U.S. pet products maker.  Antitrust regulators on both sides of the Atlantic have recently cracked down on Big Tech and Big Pharma acquiring start-ups or small rivals in order to shut them down in what is known as killer acquisitions.  Zoetis' Librela is currently the first and only monoclonal antibody medicine approved in Europe to treat pain associated with osteoarthritis in dogs.","url":"https://finance.yahoo.com/news/1-zoetis-eu-antitrust-crosshairs-142714371.html"},{"category":"company","date":1711460097,"headline":"Zoetis in EU antitrust crosshairs over rival dog pain medicine","id":126691734,"image":"https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png","symbol":"ZTS","publisher":"Yahoo","summary":"(Reuters) -EU antitrust regulators have started an investigation into whether Zoetis blocked the market launch of a rival pain medicine for dogs, the European Commission said on Tuesday, a move that could result in a hefty fine for the U.S. pet products maker.  Antitrust regulators on both sides of the Atlantic have recently cracked down on Big Tech and Big Pharma acquiring start-ups or small rivals in order to shut them down in what is known as killer acquisitions.  Zoetis' Librela is currently the first and only monoclonal antibody medicine approved in Europe to treat pain associated with osteoarthritis in dogs.","url":"https://finance.yahoo.com/news/eu-targets-zoetis-antitrust-investigation-133457163.html"},{"category":"company","date":1711459800,"headline":"EU targets Zoetis in antitrust investigation over dog medicines","id":126691736,"image":"","symbol":"ZTS","publisher":"Yahoo","summary":"The European Commission on Tuesday said it had opened an antitrust investigation into possible breaches of EU competition rules by U.S. pet products maker Zoetis.  The EU's executive said Zoetis was seen to have prevented the market launch of a novel biologic medicine used to treat chronic pain in dogs, which would have been a competitor for its 'Librela' medicine.  The EU said this meant Zoetis might have engaged in \"exclusionary behaviour\" by terminating the development of an alternative product that was going to be commercialised in Europe by a third party.","url":"https://finance.yahoo.com/news/eu-targets-zoetis-antitrust-investigation-133000145.html"},{"category":"company","date":1711454413,"headline":"Investing in Zoetis (NYSE:ZTS) five years ago would have delivered you a 71% gain","id":126691738,"image":"https://media.zenfs.com/en/simply_wall_st__316/8b2f1fb8ed1ddbd9c7702732b1ea0316","symbol":"ZTS","publisher":"Yahoo","summary":"Zoetis Inc. ( NYSE:ZTS ) shareholders might be concerned after seeing the share price drop 15% in the last month. On...","url":"https://finance.yahoo.com/news/investing-zoetis-nyse-zts-five-120013365.html"},{"category":"company","date":1711451160,"headline":"Zoetis comes under EU antitrust probe over dog pain drug","id":126690929,"image":"","symbol":"ZTS","publisher":"Seeking Alpha","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3415717448"},{"category":"company","date":1711450731,"headline":"Zoetis to Be Investigated by EU Over Possible Breach of Competition Rules -- 2nd Update","id":126689090,"image":"","symbol":"ZTS","publisher":"Finnhub","summary":"By Ian Walker The European Commission has started a formal investigation into animal health company Zoetis to see if it broke competition rules by preventing the launch of a competing pain...","url":"https://finnhub.io/api/news?id=a439c83b30927e21a3efc1ff181fbc7c252cb581ec5233751f53da9bdce5efee"},{"category":"company","date":1711449088,"headline":"EU to Investigate Zoetis Over Possible Breach of Competition Rules -- Update","id":126688740,"image":"","symbol":"ZTS","publisher":"Finnhub","summary":"By Ian Walker The European Commission has started a formal investigation into animal health company Zoetis to see if it broke competition rules by preventing the launch of a competing pain...","url":"https://finnhub.io/api/news?id=edf01b27e6e86bc6c7bcc118869e4bcd9d2edd4e8f6b764662c5790bb464cec9"},{"category":"company","date":1711446963,"headline":"EU to Investigate Zoetis Over Possible Breach of Competition Rules","id":126688278,"image":"","symbol":"ZTS","publisher":"Finnhub","summary":"By Ian Walker The European Commission has started a formal investigation into animal health company Zoetis to see if it broke competition rules by preventing the launch of a competing pain...","url":"https://finnhub.io/api/news?id=6a833ce595df52054de253e3a5eb67703cfcd6debfc0b55cc8d46dd7fd944ee4"},{"category":"company","date":1711389580,"headline":"You Don't Have To Take Excess Risk To Beat The Market","id":126678251,"image":"","symbol":"ZTS","publisher":"SeekingAlpha","summary":"","url":"https://seekingalpha.com/article/4680345-you-dont-have-to-take-excess-risk-to-beat-the-market"},{"category":"company","date":1711108810,"headline":"Does Zoetis (NYSE:ZTS) Deserve A Spot On Your Watchlist?","id":126642559,"image":"","symbol":"ZTS","publisher":"Yahoo","summary":"Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...","url":"https://finance.yahoo.com/news/does-zoetis-nyse-zts-deserve-120010236.html"},{"category":"company","date":1711033914,"headline":"Zoetis: My Favorite Healthcare Stock Right Now","id":126620991,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1471774638/image_1471774638.jpg?io=getty-c-w1536","symbol":"ZTS","publisher":"SeekingAlpha","summary":"Zoetis has a strong position in the animal health market, with increased pricing power and limited competition. Click here for why I am bullish on ZTS stock.","url":"https://seekingalpha.com/article/4679714-zoetis-my-favorite-healthcare-stock-right-now"},{"category":"company","date":1711007580,"headline":"Discounted Zoetis price offers buing opportunity, says Argus","id":126644070,"image":"","symbol":"ZTS","publisher":"Thefly.com","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3408438167"},{"category":"company","date":1710765660,"headline":"10 Health Care Stocks Whale Activity In Today's Session","id":126557595,"image":"","symbol":"ZTS","publisher":"Benzinga","summary":"Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.","url":"https://www.zacks.com/research/get_news.php?id=3403541546"},{"category":"company","date":1710744385,"headline":"More Big Changes To My Dividend Growth Portfolio","id":126552676,"image":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1072593728/image_1072593728.jpg?io=getty-c-w1536","symbol":"ZTS","publisher":"SeekingAlpha","summary":"I have been actively reshaping my portfolio by selling off low-conviction holdings and focusing on high-growth compounders. Explore more details here.","url":"https://seekingalpha.com/article/4678836-more-big-changes-to-my-dividend-growth-portfolio"},{"category":"company","date":1710430234,"headline":"Zoetis (ZTS) Down 4.3% Since Last Earnings Report: Can It Rebound?","id":126504040,"image":"","symbol":"ZTS","publisher":"Yahoo","summary":"Zoetis (ZTS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.","url":"https://finance.yahoo.com/news/zoetis-zts-down-4-3-153034578.html"}]}